Summit Expands Ivonescimab Development Into Biliary Tract Cancer

Impact · against what's priced in

The move into biliary tract cancer provides a near-term catalyst for Summit Therapeutics by expanding its potential addressable market, which the market currently discounts. For AstraZeneca and Merck, the news represents a competitive threat as their established treatments become benchmarks for a potential superior successor.

SMMT+0.40

Challenges what's priced in

The price assumes